Patients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb's immunotherapy Opdivo with Ipsen's targeted drug Cabometyx, ahead o
A phase 1 trial of Allogene's of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA, after a "chromosomal abnormality" was seen in a patient receiving the cell therapy.
Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca and Daiichi Sankyo have claimed FDA breakthrough status for the drug that should